Cushing's SyndromeNCT07282223
Contralateral Adrenal Volume Predicts Duration of Postoperative Steroid Replacement Therapy in Non-ACTH-dependent Hypercortisolism
An observational study of Cushing's Syndrome and Postoperative, run by Peking University First Hospital at 1 site in China.
Trial summary
To identify preoperative factors influencing the duration of steroid replacement therapy after adrenalectomy/adrenal-sparing surgery in patients with non-ACTH-dependent hypercortisolism. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Cushing's Syndrome, Postoperative, Glucocorticoid
- What is being tested?
- observational diagnostic model development
- How many people
- 121 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2017to 1 Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- Adult, Older adult
Study population: In all, 111 patients (meadian age: 54years; 64.9% female) were included and received postoperative steroid replacement therapy, among whom 65 were diagnosed with subclinical Cushing's syndrome (SCS) and 46 with overt Cushing's syndrome (CS).
Who may be able to join
- In all, 111 patients (meadian age: 54years; 64.9% female) were included and received postoperative steroid replacement therapy, among whom 65 were diagnosed with subclinical Cushing's syndrome (SCS) and 46 with overt Cushing's syndrome (CS).
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Urology, Peking University First Hospital, Beijing, 100034
Beijing
About this study
To identify preoperative factors influencing the duration of steroid replacement therapy after adrenalectomy/adrenal-sparing surgery in patients with non-ACTH-dependent hypercortisolism.
- Conditions
- Cushing's Syndrome, Postoperative, Glucocorticoid, Prediction
- Being tested
- observational diagnostic model development
- Medical subject headings
- Cushing Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
observational diagnostic model developmentOther
observational diagnostic model development
What is being measured
The primary outcome is the main question the study is designed to answer.
Tumor volume
Measured: from 2017 to 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2025
- Study start1 Aug 2017
- Primary completion1 Apr 2025
- Study completion1 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cushing's SyndromeStudies of the same condition, open and under way.
- More trials run by Peking University First HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 121 participants (actual)
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07282223
- Sponsor's protocol ID
- PKUFH-CS-CAV-001
- Status last verified
- Aug 2025
- First submitted
- 2 Dec 2025
- Last updated
- 15 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Contralateral Adrenal Volume Predicts Duration of Postoperative Steroid Replacement Therapy in Non-ACTH-dependent Hypercortisolism
- ClinicalTrials.gov ID
- NCT07282223
- Acronym / sponsor ID
- PKUFH-CS-CAV-001
- Conditions
- Cushing's Syndrome, Postoperative, Glucocorticoid, Prediction
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 121 participants (actual)
- Lead sponsor
- Peking University First HospitalUniversity, hospital or other
- Study start
- 1 Aug 2017 (actual)
- Primary completion
- 1 Apr 2025 (actual)
- Study completion
- 1 Apr 2025 (actual)
- First posted
- 15 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To identify preoperative factors influencing the duration of steroid replacement therapy after adrenalectomy/adrenal-sparing surgery in patients with non-ACTH-dependent hypercortisolism.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- In all, 111 patients (meadian age: 54years; 64.9% female) were included and received postoperative steroid replacement therapy, among whom 65 were diagnosed with subclinical Cushing's syndrome (SCS) and 46 with overt Cushing's syndrome (CS).
Key inclusion criteria (1 listed)
- In all, 111 patients (meadian age: 54years; 64.9% female) were included and received postoperative steroid replacement therapy, among whom 65 were diagnosed with subclinical Cushing's syndrome (SCS) and 46 with overt Cushing's syndrome (CS).
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| observational diagnostic model developmentobservational diagnostic model development | Other | – |
Primary outcome
Tumor volume
Time frame: from 2017 to 2025
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2025.
- Individual participant dataSharing planned: Yes
Related trials for Cushing's Syndrome
Not yet recruitingPhase 2
Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2)
Active, not recruitingPhase 2
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Cushing Syndrome
RecruitingPhase 1/2
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
Cushing s Syndrome
RecruitingPhase 4
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Hypertension, Hypercortisolemia
RecruitingObservational study
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Cushing's Disease, Cushing Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cushing's Syndrome and Postoperative, run by Peking University First Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tumor volume (time frame: from 2017 to 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2025.